Latest Financial Position News

Avecho Biotechnology reported a 79% revenue increase driven by a $4.8 million upfront licensing fee from Sandoz, yet its half-year loss grew 23% as R&D and administrative costs rose. The company advances its Phase III CBD insomnia trial while pursuing further international licensing.

Imugene Limited has successfully closed its Share Purchase Plan, raising $2.42 million following a $22.5 million institutional placement, reinforcing its capital position for ongoing immuno-oncology development.

Humm Group Limited has announced a fully franked ordinary dividend of AUD 0.0075 per share for the six months ending June 2025, alongside a Dividend Reinvestment Plan offering.

hummgroup reports a robust 57% increase in FY25 cash profit to $52.9 million, driven by asset growth and operational efficiencies, while navigating regulatory changes and elevated credit losses.

Aeris Resources Limited reported a robust financial turnaround for FY25, posting a $45.2 million profit and a 68% rise in adjusted EBITDA, underpinned by steady copper and gold production and strategic refinancing.

Clarity Pharmaceuticals reported a $64.3 million loss for FY2025 alongside significant clinical progress and a $203.6 million placement to fund its radiopharmaceutical pipeline expansion.

Percheron Therapeutics posted a 25% increase in net loss for FY2025 amid termination of its Duchenne Muscular Dystrophy programs. The company pivots strategically to oncology with the in-licensing of HMBD-002, a monoclonal antibody targeting VISTA, aiming to initiate Phase II trials in 2026.

Airtasker Limited reported a 12.8% increase in revenue to $52.6 million for FY25, driven by growth in Australia, the UK, and the US. However, the company’s net loss widened significantly to $37.7 million, reflecting heavy investment in global marketing and media partnerships.

Kingsgate Consolidated Limited reports a robust financial turnaround in FY2025, driven by resumed mining operations and record production at Chatree Gold Mine. Revenue more than doubled, while net profit rebounded to A$29.5 million.

Orcoda Limited reported a 33% drop in FY25 revenue to $17.16 million and a net loss of $2.5 million, driven by deferred projects in its Resource & Infrastructure division. Meanwhile, its Transport Technology division posted EBITDA growth, signaling a potential turnaround.

Nickel Industries reported a robust 81% rise in half-year profit to US$25.5 million, while advancing the Excelsior Nickel Cobalt project towards commissioning. The company also declared a final dividend and highlighted sustainability achievements.

Nuchev Limited reported a strong FY25 with revenue doubling to $22.9 million, driven by growth in Oli6® Nutritionals and the integration of bWellness Practitioner channel. Adjusted EBITDA loss narrowed significantly amid improved margins and cost control.